key: cord-1026765-u5ia060s
authors: Ilias, Ioannis; Diamantopoulos, Aristidis; Botoula, Efthymia; Athanasiou, Nikolaos; Zacharis, Alexandros; Tsipilis, Stamatios; Jahaj, Edison; Vassiliou, Alice G.; Vassiliadi, Dimitra A.; Kotanidou, Anastasia; Tsagarakis, Stylianos; Dimopoulou, Ioanna
title: Covid-19 and Growth Hormone/Insulin-Like Growth Factor 1: Study in Critically and Non-Critically Ill Patients
date: 2021-06-16
journal: Front Endocrinol (Lausanne)
DOI: 10.3389/fendo.2021.644055
sha: 92f2f77daa4e0d0c39bdfeab73613d2e10f9a7fa
doc_id: 1026765
cord_uid: u5ia060s

OBJECTIVE: We aimed to measure insulin-like growth factor 1 (IGF1) and growth hormone (GH) in critically and non-critically ill patients with Covid-19 and assess them vis-a-vis clinical and laboratory parameters and prognostic tools. SUBJECTS AND METHODS: We included patients who were admitted to the wards or the ICU of the largest Covid-19 referral hospital in Greece; patients with non-Covid-19 pneumonia served as controls. Apart from the routine laboratory work-up for Covid-19 we measured GH and IGF1 (and calculated normalized IGF-1 values as standard deviation scores; SDS), after blood sampling upon admission to the wards or the ICU. RESULTS: We studied 209 critically and non-critically ill patients with Covid-19 and 39 control patients. Patients with Covid-19 who were ICU non-survivors were older and presented with a worse hematological/biochemical profile (including white blood cell count, troponin, glucose, aminotransferases and lactate dehydrogenase) compared to ICU survivors or Covid-19 survivors in the wards. Overall, IGF-1 SDS was higher in Covid-19 survivors compared to non-survivors (-0.96 ± 1.89 vs -2.05 ± 2.48, respectively, p=0.030). No significant differences were noted in GH between the groups. Nevertheless, in critically ill patients with Covid-19, the prognostic value of IGF-1 (raw data), IGF-1 (SDS) and GH for survival/non-survival was on a par with that of APACHE II and SOFA (with a marginal difference between GH and SOFA). CONCLUSION: In conclusion, our findings suggest that there might be an association between low IGF1 (and possibly GH) and poor outcome in patients with Covid-19.

The novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), affects primarily the respiratory tract, but may also cause multi-organ dysfunction due to the widespread presence of angiotensin-converting enzyme-2 (ACE-2) receptors, an entry point for the virus (1) . As far as the endocrine glands are concerned, changes in thyroid, pancreas, adrenals and gonads are increasingly being reported (2) . Despite these, no clinical study has investigated the potential link between SARS-CoV-2 and the growth hormone (GH)/insulinlike growth factor-1 (IGF1) axis. A study has been done on laboratory results of Covid-19 patients from the UK Biobank (3) and another molecular study has been done with few patients (n=20) (4) . Recently, speculation on diminished GH action in patients with Covid-19 has been put forth in this Journal (5) . In this observational study we measured IGF1/GH in patients with Covid-19, hospitalized in the ward or the Intensive Care Unit (ICU) and assessed their levels vis-a-vis clinical and laboratory parameters and prognostic tools.

In this study we included only patients with Covid-19 (verified with polymerase chain reaction; PCR) who were admitted -from April 2020 to October 2020 -to the wards or the ICU of the largest Covid-19 referral hospital (with approximately 1000 hospital beds in total) in Athens, Greece. Patients in other wards with non-Covid-19 pneumonia served as contemporaneous controls. Patients receiving dexamethasone were excluded. Apart from the routine laboratory work-up for Covid-19 we also measured morning GH and IGF1 within 48 hours of admission to the wards or the ICU (GH and IGF1 were measured with the Immulite 2000 hGH and  IGF1 Assays and Analyzer, Siemens Healthcare GmbH, 91052 Erlangen, Germany). We also normalized IGF-1 values by age/ gender and expressed them as standard deviation scores (SDS), per the procedure described by Chanson 

We studied 209 critically and non-critically ill patients with Covid-19; 39 wards' patients with non-Covid-19 pneumonia served as contemporaneous controls. The patients' demographics and laboratory evaluation results are presented in Tables 1 and 2. Patients who were ICU non-survivors were older and presented with a worse hematological/biochemical profile (including white blood cell count, troponin, glucose, aminotransferases and lactate dehydrogenase) compared to ICU survivors or Covid-19 survivors in the wards. Overall, no significant differences were noted in GH between all the groups, whereas IGF-1 SDS was higher in Covid-19 survivors compared to non-survivors (-0.96 ± 1.89 vs -2.05 ± 2.48, respectively, p=0.030); also the lowest IGF-1 SDS was in Covid-19 ICU non-survivors, whereas the highest was in non-Covid-19 controls that survived ( Table 1 ). In critically and non-critically ill Covid-19 patients there were negative correlations between IGF1 and age (r= -0.49, p<0.0001), C-reactive protein (CRP; r= -0.34, p<0.0001), LDH (r=-0.38, p<0.0001), % of lymphocytes (r=-0.22, p=0.01) and % of neutrophils (r=-0.22, p=0.01). In a ROC plot of IGF-1/IGF-1 SDS or GH versus survival in the ICU patients, the areas under the curve (AUC) for IGF-1/IGF-1 SDS were similar to that of scores of well-established prognostic tools (namely the Acute Physiologic Assessment and Chronic Health Evaluation II; APACHE II, and Sequential Organ Failure Assessment; SOFA scores), whereas a marginal difference was noted for GH versus SOFA ( Figure 1 and Table 3 ). Regarding the analysis of IGF-1/IGF-1 SDS levels, as assessed in four (Covid-19 only) or six groups (Covid-19 and non-Covid-19 controls), the attained power was 0.662 or 0.697 and 0.658 or 0.694, respectively, whereas for GH the power was 0.546 or 0.475, respectively.

In this observational study we noted lower IGF-1 SDS in critically ill Covid-19 patients compared to their counterparts with less severe disease or without Covid-19. Of importance, we also found that non-survivors had lower IGF-1 SDS than survivors.

GH and IGF1, the most important mediator of GH effects, apart their role in growth regulation during childhood, coordinate several processes throughout adult life (7, 8) . GH stimulates protein synthesis, increases lipolysis, and potentiates the action of insulin (9) . Moreover, IGF1 has been found to be pro-survival/anti-aging, anti-inflammatory, and antioxidant with neuro-and hepatoprotective properties (10) . IGF-1 exerts beneficial effects over mitochondria by preserving it from the oxidative damage (10) . Although the majority of data on the relation between GH and the immune system are from animal studies, it seems that GH may possess useful immunomodulatory actions. Normal aging is associated with a gradual decline in serum GH and the decline is more rapid in men than in women (10) . Of note, the susceptibility of Covid-19 infection has been reported to be gender-and age-dependent and immune system dysfunction has been found to play a key role for poor clinical outcome (11) (12) (13) . Despite these, the specific question about the impact of Covid-19 on GH/IGF1 axis remains currently unanswered. The only issue that has been previously addressed is whether the Covid-19 pandemic has affected the treatment adherence in patients with known GH deficiency (14) . In our study, we measured GH and IGF-1 in a relatively large series with mild-to-critical Covid-19. We found that IGF-1 SDS levels were lower in Covid-19 patients who did not survive (particularly the ones who were mechanically ventilated). Moreover, IGF1 was inversely related with age, and markers of Covid-19 severity, i.e. LDH, CRP, % of lymphocytes and neutrophils. Sarcopenia in malnutrition/cachexia may be associated with lowering of IGF1 levels in muscle tissue or plasma (15, 16) . Patients with Covid-19 are often malnourished (17) and with clinical sarcopenia. The latter is also attributed to excess cytokines' production and action, disease severity status and immobilization (18) . These causes (and in particular malnutrition) may also explain -in part -the IGF1 findings in our patients. Taken together, our results raise the possibility that there might be a link between low IGF-1, Covid-19 severity and poor outcome. To our knowledge, such findings have not been previously reported.

In critically ill patients, although GH secretion increases, hepatic GH receptors become downregulated and circulating IGF1 has been shown to decrease appreciably (5, 19) . Prognostic value has been suggested for GH versus ICU survival in the past (20) ; in our patients, IGF1 vis-à-vis prognosis was on a par with accepted prognostic tools (Acute Physiologic Assessment and Chronic Health Evaluation II; APACHE II (21) and Sequential Organ Failure Assessment; SOFA (22) ) and GH had a significantly higher AUC in ROC plot analysis compared to SOFA, a widely accepted scoring system assessing degree of organ dysfunction in ICU patients.

Older, prospective, randomized, placebo-controlled trials showed unexpectedly that the administration of recombinant human GH (rhGH) was associated with a marked increase in mortality in the rhGH group (23, 24) . The main explanation for this untoward result was considered to be the high dosage of rhGH (24) .

Our study lends credence to the known finding of the negative effect of age on IGF-1 (25) , and the finding of lower mortality in patients with Covid-19 that have IGF-1 in the highest quartile compared to those patients that have IGF-1 in the lowest quartile (3) (though the latter finding was presented with no regard to severity of disease or localization of hospitalization i.e. wards or ICU). Of note, in a small (n=10) recent proteomic analysis study of plasma from critically ill Covid-19 patients, increased expression of the IGF-1 receptor was found, but no association was reported with regards to survival (4).

In the ever-shifting vista of Covid-19 many diagnostic and therapeutic means have been assessed in an effort to understand disease pathogenesis and tame the pandemic. Since studies of patients with Covid-19 and information on GH/IGF-1 (and their possible effect on disease outcomes) are scarce, we believe that this study contributes to the understanding of the disease. The study does not assess the presence of other associated disorders that may have contributed to the reduction of IGF-1 such as obesity, hepatic and renal dysfunction or acidosis. Any interference of medications such as anticoagulants in the measurement methods was not evaluated; IGF binding proteins or heterophilic antibodies (known to interfere with the measurement of IGF-1) were also not assessed. One could argue that the findings may be due only to the age of the patients, since IGF-1 is known to decrease with advanced age, although differences among the study groups were more pronounced with age/gender normalized IGF-1 SDS compared to raw IGF-1 levels. It is true that any cost-effectiveness or cost-benefit of measuring IGF-1/GH was not appraised in our work; we also have to acknowledge this as a limitation of this study. Another limitation of this study is that, at this sample size, the (a posteriori calculated) attained power was rather low.

In conclusion, our findings suggest that there might be an association between low IGF1 (and possibly GH) and poor outcome in patients with Covid-19. Thus, the question whether GH supplementation at appropriate dosages could be of therapeutic benefit in specific (possibly older) patients with Covid-19 and with concomitant GH deficiency, receiving ICU support, seems to be plausible.

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

The studies involving human participants were reviewed and approved by the Scientific Council/Ethics Board of the Evangelismos Hospital (No 170/April 24, 2020). The patients/ participants provided their written informed consent to participate in this study. 

The GH/IGF-1 System in Critical Illness

SARS-Cov-2 (COVID-19) and the Endocrine System

Pre-Diagnostic Circulating Concentrations of Insulin-Like Growth Factor-1 and Risk of COVID-19 Mortality: Results From UK Biobank

Novel Outcome Biomarkers Identified With Targeted Proteomic Analyses of Plasma From Critically Ill Coronavirus Disease 2019 Patients

A Suggested Role of Human Growth Hormone in Control of the COVID-19 Pandemic

Reference Values for IGF-I Serum Concentrations: Comparison of Six Immunoassays

Biology of the Somatotroph Axis (After the Pituitary)

The Intricate Role of Growth Hormone in Metabolism

The Growth Hormone Signaling System: Insights Into Coordinating the Anabolic and Catabolic Actions of Growth Hormone

Effects of GH/IGF on the Aging Mitochondria

Gender Differences in Patients With COVID-19: A Narrative Review

Impact of Sex and Gender on COVID-19 Outcomes in Europe

COVID-19 in Older People: A Rapid Clinical Review

Growth Hormone Deficiency, Acromegaly and COVID-19: Transitioning From Media Reports to Knowledge and a Growth Hormone Hypothesis

Regulation of Muscle Protein Synthesis and the Effects of Catabolic States

Nutritional Laboratory Markers in Malnutrition

Approaches to Nutritional Screening in Patients With Coronavirus Disease 2019 (COVID-19)

Skeletal Muscle Damage in COVID-19: A Call for Action

IGF-I Concentration and Changes in Critically Ill Patients

Circulating Levels of GH Predict Mortality and Complement Prognostic Scores in Critically Ill Medical Patients

APACHE II: A Severity of Disease Classification System

Sepsis-Related Organ Failure Assessment) Score to Describe Organ Dysfunction/Failure

Safety Aspects of Pharmacological GH Therapy in Adults

Adult Growth Hormone Deficiency -Benefits, Side Effects, and Risks of Growth Hormone Replacement

Growth Hormone Dynamics in Healthy Adults are Related to Age and Sex and Strongly Dependent on Body Mass Index